TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02408120
Drug: Supplemental insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart will be administered following the supplemental insulin scale protocol.~For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:~* BG \>141-180 mg/dL; 2-4 units of insulin aspart~* BG between 181-220 mg/dL; 3-6 units of insulin aspart~* BG between 221-260 mg/dL; 4-8 units of insulin aspart~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG \> 400 mg/dL; 8-16 units of insulin aspart~For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG \> 400 mg/dL; 8-16 units of insulin aspart
Study: NCT01047891
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
Study: NCT00471991
Drug: SH T04769G
Normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.
Study: NCT03754530
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally three times per day
Study: NCT03558139
Drug: Magrolimab
Normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT03558139
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT02023840
Drug: metronidazole gel
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01826916
Drug: DX-88 (ecallantide)
Normalized name: DX-890
DrugBank: Depelestat (DB17873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection 10 mg/mL
Study: NCT00551616
Drug: Levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose
Study: NCT03946917
Drug: regorafenib tablet
Normalized name: Regorafenib Tablets
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 80/120/160 mg, po, d1-d21, Q4w.
Study: NCT02588196
Drug: Dexamethasone acetate
Normalized name: Dexamethasone Acetate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02010255
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV tablets administered orally in a divided daily dose
Study: NCT00855764
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent
Study: NCT03226171
Drug: Dose-adjusted SK-1403
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment
Study: NCT03753776
Drug: Placebo pills of Radium bromatum
Normalized name: radium
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo pills of Radium bromatum will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
Study: NCT03753776
Drug: Radium bromatum pills
Normalized name: radium
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homeopathic Radium bromatum pills will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
Study: NCT03753776
Drug: Radium bromatum/Apis mellifica/Belladonna placebo pills
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
Study: NCT03753776
Drug: Radium bromatum/Apis mellifica/Belladonna pills
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
Study: NCT00280969
Drug: atazanavir arm
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
Study: NCT00280969
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are treated with efavirenz 300mg along with Epzicom.
Study: NCT01275560
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole,per os,500mg, 3 per day during 10 days
Study: NCT01275560
Drug: CArbosylane
Normalized name: pyrrolidone carboxylate
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00754494
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02116894
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
Study: NCT04750382
Drug: HX008+Cisplatin+Gemcitabine
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive HX008 3mg/kg, Day 1,Q3W for up to 2 years + Cisplatin 75mg/m\^2, Day 1, Q3W for up to 6 cycles +Gemcitabine 1250mg/m\^2, Day 1, Day 8, Q3W for up to 6 cycles
Study: NCT03485846
Drug: Narlaprevir
Normalized name: narlaprevir
DrugBank: Narlaprevir (DB14760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, oval shaped, concave, yellow film-coated, tablets taken as 200 mg per os daily
Study: NCT03485846
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg, tablets, taken as 100 mg per os daily
Study: NCT03485846
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60 mg, tablets, taken as 60 mg per os daily
Study: NCT00932217
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneous filgrastim administration
Study: NCT00932217
Drug: lenograstim
Normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous lenograstim administration
Study: NCT02540837
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Obturator nerve block
Study: NCT02540837
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Obturator nerve block with saline(placebo)
Study: NCT03795389
Drug: DM199
Normalized name: Recombinant Human Tissue Kallikrein-1
DrugBank: Recombinant human kallikrein-1 (DB19232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC dose
Study: NCT00939627
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT05680792
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days
Study: NCT05680792
Drug: Atazanavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300/100 mg atazanavir/ritonavir tablets in the evening once daily, to be administered after meal for 5 days.
Study: NCT03396874
Drug: 68Ga-PSMA
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi).
Study: NCT03668431
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib will be taken twice a day for 28 consecutive days~.
Study: NCT03668431
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib will be taken once a day for 28 consecutive days
Study: NCT00977431
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
Study: NCT01884402
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment as usual clinical practice
Study: NCT01884402
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment as usual clinical practice
Study: NCT01483014
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01445418
Drug: AZ2281 + Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cohort 1: Dose escalation: AZD2281 po bid qd + IV carboplatin D8 of each 21-day cycle.; Cohort 2: Expanded cohort treated at the MTD of the combination identified in Cohort 1.
Study: NCT01876368
Drug: Olmesartan
Normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01876368
Drug: Placebo of Olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03340506
Drug: dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dabrafenib is available in capsules (50mg and 75mg) taken twice a day
Study: NCT03340506
Drug: trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: trametinib is available in tablets (0.5mg, 2mg dose)
Study: NCT04099641
Drug: Bavituximab
Normalized name: Bavituximab
DrugBank: Bavituximab (DB05136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavituximab IV infusion
Study: NCT04099641
Drug: Pembrolizumab Injection
Normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab IV Infusion
Study: NCT01391845
Drug: ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30mg of ulipristal acetate orally the day of hCG injection in a unique dose
Study: NCT01391845
Drug: ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ulipristal acetate 30mg orally in a unique dose the day of hCG administration
Study: NCT02563769
Drug: Clavulanic acid
Normalized name: Clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clavulanic acid will be administered orally in 250mg capsules
Study: NCT02563769
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/40mg Cocaine will be administered by IV
Study: NCT02078921
Drug: Sodium Nitrate
Normalized name: Sodium Nitrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00689845
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given subcutaneously
Study: NCT00689845
Drug: etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00689845
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00689845
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00689845
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00689845
Drug: vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00738361
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg/m2 weekly for 3 of 4 weeks every 28 days.
Study: NCT01661634
Drug: Ularitide
Normalized name: Ularitide
DrugBank: Ularitide (DB05034)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03823287
Drug: Faricimab
Normalized name: Faricimab
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
Study: NCT03823287
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
Study: NCT01109758
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 145 mg
Study: NCT04991012
Drug: Triamcinolone (Substance) therapy side
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: th The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
Study: NCT04686994
Drug: ASC 41
Normalized name: ASC
DrugBank: N-acetylsulfanilyl chloride (DB12337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT00190489
Drug: Docetaxel 60mg/m2 every 21 days for 6 cycles
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00190489
Drug: AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02079337
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02079337
Drug: sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03666325
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab at 200 mg every 3 weeks for 9 weeks.
Study: NCT03666325
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In case of first progression or no response cetuximab will be added at a weekly dose of 250 mg.
Study: NCT03304288
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low-dose rituximab was used in combination with ATRA or as the monotherapy
Study: NCT03304288
Drug: All-trans retinoic acid
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA was used in combination with low-dose rituximab
Study: NCT00932724
Drug: CY-503
Normalized name: Cys
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
Study: NCT00707421
Drug: fluorometholone
Normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01168687
Drug: Levetiracetam (Keppra)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group A: Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.~Group B: Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.
Study: NCT02425501
Drug: Aflibercept (Eylea, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration by intravitreal injection
Study: NCT01891812
Drug: Nitrous oxide 50%
Normalized name: Nitrous oxide 50% and oxygen 50% gas for inhalation
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01044394
Drug: polyethylene glycol (PEG-ELS) and bisacodyl tablets
Normalized name: Polyethylene Glycol
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
Study: NCT01118026
Drug: ABVD
Normalized name: Adriamycin, Bleomycin, Vinblastine, Dacarbazine
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin 25 mg/m\^2 IV bleomycin 10 units/m\^2 IV vinblastine 6 mg/m\^2 IV dacarbazine 375 mg/m\^2 IV
Study: NCT00831233
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
Study: NCT00831233
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
Study: NCT00831233
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
Study: NCT00135720
Drug: Enbrel (Etanercept)
Normalized name: etanercept Cartridge [Enbrel]
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06677853
Drug: Timolol Maleate Gel+Placebo
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects were applied with the 0.5% timolol maleate gel at the affected area twice a day, and with the placebo once a day for 24 weeks.
Study: NCT06677853
Drug: Timolol Maleate Gel
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects were applied with the 0.5% timolol maleate gel at the affected area 3 times a day for 24 weeks.
Study: NCT04253353
Drug: tafamidis
Normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 61 mg capsule
Study: NCT00648245
Drug: BIO-11006 Inhalation Solution
Normalized name: Bio-Kool
DrugBank: BIO-11006 (DB14886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of BIO-11006 administered once per day for 21 days by nebulizer
Study: NCT00648245
Drug: BIO-11006 Inhalation Solution
Normalized name: Bio-Kool
DrugBank: BIO-11006 (DB14886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of BIO-11006 administered once per day for 21 days by nebulizer
Study: NCT00648245
Drug: BIO-11006 Inhalation Solution
Normalized name: Bio-Kool
DrugBank: BIO-11006 (DB14886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
Study: NCT00648245
Drug: BIO-11006
Normalized name: BIO-11006
DrugBank: BIO-11006 (DB14886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg BIO-11006 given twice per day for 21 days by nebulizer
Study: NCT03594825
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Different time of taking medicine
Study: NCT00042172
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00042172
Drug: Ginkgo Biloba Extract
Normalized name: Ginkgo biloba extract
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03936218
Drug: Inj. Goserelin (Test) Subcutaneously
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10.8 mg, subcutaneously at every 3 month
Study: NCT00036504
Drug: Insulin Lispro low mixture
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03965728
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For all dose steps. Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2
Study: NCT02265406
Drug: Anti-Infective Agents
Normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01901848
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.